Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RHOA | P61586 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378969 | 0.89 | DPP7 (0.52) | GRM5NTRK1DPP7ALDH1A1RHOA | |
| SCHEMBL3237608 | 0.87 | GRM5 (0.75) | GRM5DPP7ALDH1A1GAAHPGD | |
| SCHEMBL3376258 | 0.86 | PPARA (0.55) | NTRK1ALDH1A1PPARA | |
| SCHEMBL3379917 | 0.86 | GRM5 (0.57) | GRM5NTRK1DPP7ALDH1A1GAA | |
| SCHEMBL3377905 | 0.84 | PPARA (0.49) | NTRK1DPP7HPGDRHOAPPARA | |
| SCHEMBL3378131 | 0.82 | PPARA (0.53) | PPARA | |
| SCHEMBL325138 | 0.81 | NTRK1 (0.44) | GRM5NTRK1DPP7ALDH1A1GAA | |
| SCHEMBL3236009 | 0.81 | GRM5 (0.64) | GRM5DPP7ALDH1A1GAAHPGD | |
| SCHEMBL3237604 | 0.79 | GRM5 (0.68) | GRM5DPP7ALDH1A1GAAHPGD | |
| SCHEMBL20394973 | 0.78 | NAMPT (0.61) | GRM5ALDH1A1GAAHPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | claimed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | claimed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | claimed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | GRM5 841/4885NTRK1 3278/4885DPP7 3180/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | GRM5 297/4885NTRK1 363/4885DPP7 3181/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | GRM5 841/4885NTRK1 3278/4885DPP7 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.